AR070842A1 - Regimen de dosificacion para un agonista de receptor selectivo de s1p1 - Google Patents
Regimen de dosificacion para un agonista de receptor selectivo de s1p1Info
- Publication number
- AR070842A1 AR070842A1 ARP090100886A ARP090100886A AR070842A1 AR 070842 A1 AR070842 A1 AR 070842A1 AR P090100886 A ARP090100886 A AR P090100886A AR P090100886 A ARP090100886 A AR P090100886A AR 070842 A1 AR070842 A1 AR 070842A1
- Authority
- AR
- Argentina
- Prior art keywords
- receptor agonist
- dose
- selective
- selective receptor
- white
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a un régimen de dosificacion para un agonista del receptor selectivo S1P1, en donde el agonista del receptor selectivo S1P1 se administra a un sujeto de modo tal que, durante la fase de tratamiento inicial, el agonista del receptor selectivo S1P1 se administra en una dosis que induce desensibilizacion del corazon, en donde dicha dosis es inferior a la dosis blanco y a una frecuencia de dosificacion que sustenta la desensibilizacion del corazon, hasta que no se produzca ninguna reduccion de la frecuencia cardíaca aguda, seguida de la titulacion de la dosis hacia arriba a la dosis blanco del agonista del receptor selectivo S1P1. Reivindicacion 6: El agonista del receptor selectivo S1P1 para usar como un medicamento de acuerdo con cualquiera de las reivindicaciones 1 a 5, en donde el agonista del receptor selectivo S1P1 es (R)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)-benc[Z]iliden]-2-([Z]-propilimino)-3-o-tolil-tiazolidin-4-ona, o una de sus sales farmacéuticamente aceptables. Reivindicacion 9: Un kit que contiene diferentes unidades de medicacion de un agonista del receptor selectivo S1P1 para administracion de acuerdo con la reivindicacion 1, en donde se proveen una o varias unidades de una potencia de dosis inferior a la dosis blanco de dicho agonista del receptor selectivo S1P1 para la fase de tratamiento inicial, y se proveen posteriores unidades de medicacion de mayores potencias de dosis hasta la dosis blanco de dicho agonista del receptor selectivo S1P1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2008050995 | 2008-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070842A1 true AR070842A1 (es) | 2010-05-05 |
Family
ID=40786618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100886A AR070842A1 (es) | 2008-03-17 | 2009-03-12 | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US8785484B2 (es) |
| EP (1) | EP2278960B2 (es) |
| JP (2) | JP4846063B2 (es) |
| KR (3) | KR101718639B1 (es) |
| CN (2) | CN101980704A (es) |
| AR (1) | AR070842A1 (es) |
| AU (1) | AU2009227629B2 (es) |
| BR (1) | BRPI0909625B1 (es) |
| CA (1) | CA2716448A1 (es) |
| CY (1) | CY1118648T1 (es) |
| DK (1) | DK2278960T4 (es) |
| ES (1) | ES2617628T5 (es) |
| HR (1) | HRP20170246T4 (es) |
| HU (1) | HUE033168T2 (es) |
| IL (1) | IL208154A (es) |
| LT (1) | LT2278960T (es) |
| MA (1) | MA32233B1 (es) |
| MX (1) | MX2010009853A (es) |
| MY (1) | MY177360A (es) |
| NZ (1) | NZ588505A (es) |
| PL (1) | PL2278960T5 (es) |
| PT (1) | PT2278960T (es) |
| RU (1) | RU2519660C2 (es) |
| SI (1) | SI2278960T2 (es) |
| TW (1) | TWI434688B (es) |
| WO (1) | WO2009115954A1 (es) |
| ZA (1) | ZA201007367B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| PL1689726T3 (pl) | 2003-11-21 | 2011-05-31 | Actelion Pharmaceuticals Ltd | Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne |
| EP2094676B1 (en) * | 2006-11-23 | 2013-04-10 | Actelion Pharmaceuticals Ltd. | New process for the preparation of 2-iminothiazolidin-4-one derivatives |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| GB0819182D0 (en) * | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| HUE026869T2 (en) * | 2008-12-22 | 2016-08-29 | Novartis Ag | Dosing regimen for fingolimod for the treatment of multiple sclerosis |
| EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| MX2012012925A (es) * | 2010-05-06 | 2012-12-17 | Novartis Ag | Regimen de dosificacion de derivados de sulfuro de diarilo. |
| PE20140216A1 (es) | 2011-01-07 | 2014-03-01 | Novartis Ag | Formulaciones inmunosupresoras |
| MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
| WO2015066515A1 (en) | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| EP3256125B1 (en) * | 2014-12-11 | 2022-01-26 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| CN116850181A (zh) * | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
| CA2973540A1 (en) | 2015-02-26 | 2016-09-01 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| MX2017016530A (es) | 2015-06-22 | 2018-03-12 | Arena Pharm Inc | Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1). |
| US11478448B2 (en) * | 2017-02-16 | 2022-10-25 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| JOP20190207A1 (ar) | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| CN114599363A (zh) | 2019-10-31 | 2022-06-07 | 爱杜西亚药品有限公司 | Cxcr7拮抗剂与s1p1受体调节剂的组合 |
| EP4415699A1 (en) | 2021-10-11 | 2024-08-21 | Laboratoires Juvise Pharmaceuticals | Methods of treating multiple sclerosis |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122011100012I1 (de) | 1992-10-21 | 2011-10-20 | Mitsubishi Tanabe Pharma Corp | 2-Amino-1, 3-propandiolverbindung und immunosuppressium. |
| HU224814B1 (en) | 1995-12-28 | 2006-02-28 | Mitsubishi Pharma Corp | Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases |
| US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| EP2030614A1 (en) | 1997-02-27 | 2009-03-04 | Novartis AG | Pharmaceutical Composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol and a lecithin |
| WO1998052944A1 (en) | 1997-05-19 | 1998-11-26 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| AU2001278135A1 (en) * | 2000-08-03 | 2002-02-18 | Cytovia, Inc. | Method of identifying immunosuppressive agents |
| US20020197256A1 (en) | 2001-04-02 | 2002-12-26 | Genentech, Inc. | Combination therapy |
| ATE324886T1 (de) | 2001-04-02 | 2006-06-15 | Astrazeneca Ab | Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp |
| US6495025B2 (en) | 2001-04-20 | 2002-12-17 | Aerovironment, Inc. | Electrochemical oxygen generator and process |
| DE60216458T2 (de) * | 2001-05-16 | 2007-09-27 | Nicholas P. Wilmette Plotnikoff | Verfahren zum auslösen einer anhaltenden immunreaktion |
| NZ529044A (en) | 2001-06-08 | 2008-03-28 | Novartis Ag | Treatment or prophylaxis of insulin-producing cell graft rejection |
| DE60235900D1 (de) | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
| DE60223699T2 (de) | 2001-09-27 | 2008-10-30 | Kyorin Pharmaceutical Co., Ltd. | Diarylsulfidderivat, dessen additionssalz und immunsuppressivum |
| EP1469863A2 (en) | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| EP1470137B1 (en) | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
| GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| TWI376363B (en) | 2002-09-24 | 2012-11-11 | Novartis Ag | Pharmaceutical combination for treating demyelinating disease |
| PE20130200A1 (es) | 2003-04-08 | 2013-03-09 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| USRE43833E1 (en) * | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| PL1689726T3 (pl) * | 2003-11-21 | 2011-05-31 | Actelion Pharmaceuticals Ltd | Pochodne 5-(benz-(z)-ylideno)tiazolidyn-4-onu jako środki immunosupresyjne |
| WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
| WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| JPWO2006041015A1 (ja) | 2004-10-12 | 2008-05-15 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| US20060090658A1 (en) * | 2004-11-01 | 2006-05-04 | Michael Phillips | Tissue marking system |
| MX2007006373A (es) | 2004-11-29 | 2007-06-20 | Novartis Ag | Regimen de dosificacion de un agonista del receptor s1p. |
| BRPI0609515A8 (pt) | 2005-03-23 | 2017-12-26 | Actelion Pharmaceuticals Ltd | Composto, composição farmacêutica, e, uso de um composto |
| WO2006100635A2 (en) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists |
| PL1863474T3 (pl) | 2005-03-23 | 2009-04-30 | Actelion Pharmaceuticals Ltd | Nowe pochodne tiofenu jako agoniści receptora 1 1-fosforanu sfingozyny |
| CA2612661A1 (en) | 2005-06-24 | 2006-12-28 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
| TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| ES2335242T3 (es) | 2006-01-24 | 2010-03-23 | Actelion Pharmaceuticals Ltd. | Derivados novedosos de piridina. |
| US7879821B2 (en) * | 2006-01-26 | 2011-02-01 | University Of Medicine And Dentistry Of New Jersey | Method for modulating inflammatory responses by altering plasma lipid levels |
| TWI392671B (zh) | 2006-09-07 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 吡啶-４-基衍生物 |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| PL2069335T3 (pl) | 2006-09-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydyn-3-ylu jako środki immunomodulujące |
| ES2393412T3 (es) | 2006-09-21 | 2012-12-21 | Actelion Pharmaceuticals Ltd. | Derivados de fenilo y su uso como inmunomoduladores |
| EP2094676B1 (en) * | 2006-11-23 | 2013-04-10 | Actelion Pharmaceuticals Ltd. | New process for the preparation of 2-iminothiazolidin-4-one derivatives |
| US8912340B2 (en) * | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| WO2009024905A1 (en) | 2007-08-17 | 2009-02-26 | Actelion Pharmaceuticals Ltd | Pyridine derivatives as s1p1/edg1 receptor modulators |
| WO2009048993A2 (en) | 2007-10-12 | 2009-04-16 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| KR101718639B1 (ko) | 2008-03-17 | 2017-03-21 | 액테리온 파마슈티칼 리미티드 | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 |
| BRPI0917923B1 (pt) * | 2008-08-27 | 2022-04-05 | Arena Pharmaceuticals Inc | Derivado de ácido tricíclico substituído, sua composição, seu uso e processo para preparar a referida composição |
| GB0819182D0 (en) * | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| SG171888A1 (en) * | 2008-12-22 | 2011-07-28 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| HUE026869T2 (en) * | 2008-12-22 | 2016-08-29 | Novartis Ag | Dosing regimen for fingolimod for the treatment of multiple sclerosis |
| JP5416600B2 (ja) | 2010-01-22 | 2014-02-12 | 株式会社日立ハイテクノロジーズ | 欠陥検査装置およびその方法 |
| MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
| EP3256125B1 (en) | 2014-12-11 | 2022-01-26 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
-
2009
- 2009-03-12 KR KR1020157002281A patent/KR101718639B1/ko active IP Right Grant
- 2009-03-12 CN CN2009801101149A patent/CN101980704A/zh active Pending
- 2009-03-12 PT PT97217038T patent/PT2278960T/pt unknown
- 2009-03-12 PL PL09721703T patent/PL2278960T5/pl unknown
- 2009-03-12 AR ARP090100886A patent/AR070842A1/es unknown
- 2009-03-12 SI SI200931616T patent/SI2278960T2/sl unknown
- 2009-03-12 US US12/922,777 patent/US8785484B2/en active Active
- 2009-03-12 RU RU2010141579/15A patent/RU2519660C2/ru active
- 2009-03-12 WO PCT/IB2009/051030 patent/WO2009115954A1/en active Application Filing
- 2009-03-12 CN CN201510090161.9A patent/CN104800208A/zh active Pending
- 2009-03-12 EP EP09721703.8A patent/EP2278960B2/en active Active
- 2009-03-12 KR KR1020147005406A patent/KR101653071B1/ko active IP Right Grant
- 2009-03-12 JP JP2011500324A patent/JP4846063B2/ja active Active
- 2009-03-12 MX MX2010009853A patent/MX2010009853A/es active IP Right Grant
- 2009-03-12 HU HUE09721703A patent/HUE033168T2/en unknown
- 2009-03-12 MY MYPI2010004328A patent/MY177360A/en unknown
- 2009-03-12 LT LTEP09721703.8T patent/LT2278960T/lt unknown
- 2009-03-12 KR KR1020107022801A patent/KR20100134032A/ko active IP Right Grant
- 2009-03-12 ES ES09721703T patent/ES2617628T5/es active Active
- 2009-03-12 AU AU2009227629A patent/AU2009227629B2/en active Active
- 2009-03-12 BR BRPI0909625-6A patent/BRPI0909625B1/pt active IP Right Grant
- 2009-03-12 NZ NZ588505A patent/NZ588505A/xx unknown
- 2009-03-12 DK DK09721703.8T patent/DK2278960T4/da active
- 2009-03-12 CA CA2716448A patent/CA2716448A1/en not_active Abandoned
- 2009-03-16 TW TW098108497A patent/TWI434688B/zh active
-
2010
- 2010-09-15 IL IL208154A patent/IL208154A/en active IP Right Grant
- 2010-10-14 ZA ZA2010/07367A patent/ZA201007367B/en unknown
- 2010-10-15 MA MA33253A patent/MA32233B1/fr unknown
-
2011
- 2011-08-30 JP JP2011186874A patent/JP4938905B2/ja active Active
-
2014
- 2014-06-18 US US14/308,598 patent/US20140303217A1/en not_active Abandoned
- 2014-07-02 US US14/322,722 patent/US10660880B2/en active Active
- 2014-07-02 US US14/322,801 patent/US20140315964A1/en not_active Abandoned
-
2015
- 2015-06-05 US US14/732,013 patent/US10251867B2/en active Active
-
2017
- 2017-02-02 CY CY20171100154T patent/CY1118648T1/el unknown
- 2017-02-15 HR HRP20170246TT patent/HRP20170246T4/hr unknown
-
2021
- 2021-09-09 US US17/470,905 patent/US20210401811A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070842A1 (es) | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| NZ749192A (en) | Ar+ breast cancer treatment methods | |
| CO6270360A2 (es) | Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos | |
| CO6361944A2 (es) | Combinacion de una insulina y un agonista de glp-1 | |
| MX2013011174A (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| AR074826A1 (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
| CY1114215T1 (el) | Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης | |
| MX2009013989A (es) | Terapia en combinacion para depresion. | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2016532516A5 (es) | ||
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| MX2013012206A (es) | Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas. | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| EA201391689A1 (ru) | Система доставки лекарственного средства | |
| BRPI0607172A2 (pt) | método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. | |
| WO2012145554A3 (en) | Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof | |
| RU2014150946A (ru) | Способ снижения веса | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли | |
| AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
| RU2013141926A (ru) | Терапевтическое применение димирацетама для предотвращения ладонно-подошвенного синдрома, вызываемого сорафенибом | |
| JP2016533856A5 (es) | ||
| MX2018001041A (es) | Concentrado que contiene alprostadil. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |